Across TCGA pan-cancer cohorts, MARCHF11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MARCHF11 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher MARCHF11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MARCHF11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
COAD, BLCA, and LGG are the cancer types where MARCHF11 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.